Recent development of contrast agents for magnetic resonance and multimodal imaging of glioblastoma

Abstract Glioblastoma (GBM) as the most common primary malignant brain tumor exhibits a high incidence and degree of malignancy as well as poor prognosis. Due to the existence of formidable blood–brain barrier (BBB) and the aggressive growth and infiltrating nature of GBM, timely diagnosis and treat...

Full description

Bibliographic Details
Main Authors: Danping Zhuang, Huifen Zhang, Genwen Hu, Bing Guo
Format: Article
Language:English
Published: BMC 2022-06-01
Series:Journal of Nanobiotechnology
Subjects:
Online Access:https://doi.org/10.1186/s12951-022-01479-6
_version_ 1811299114805100544
author Danping Zhuang
Huifen Zhang
Genwen Hu
Bing Guo
author_facet Danping Zhuang
Huifen Zhang
Genwen Hu
Bing Guo
author_sort Danping Zhuang
collection DOAJ
description Abstract Glioblastoma (GBM) as the most common primary malignant brain tumor exhibits a high incidence and degree of malignancy as well as poor prognosis. Due to the existence of formidable blood–brain barrier (BBB) and the aggressive growth and infiltrating nature of GBM, timely diagnosis and treatment of GBM is still very challenging. Among different imaging modalities, magnetic resonance imaging (MRI) with merits including high soft tissue resolution, non-invasiveness and non-limited penetration depth has become the preferred tool for GBM diagnosis. Furthermore, multimodal imaging with combination of MRI and other imaging modalities would not only synergistically integrate the pros, but also overcome the certain limitation in each imaging modality, offering more accurate morphological and pathophysiological information of brain tumors. Since contrast agents contribute to amplify imaging signal output for unambiguous pin-pointing of tumors, tremendous efforts have been devoted to advances of contrast agents for MRI and multimodal imaging. Herein, we put special focus on summary of the most recent advances of not only MRI contrast agents including iron oxide-, manganese (Mn)-, gadolinium (Gd)-, 19F- and copper (Cu)-incorporated nanoplatforms for GBM imaging, but also dual-modal or triple-modal nanoprobes. Furthermore, potential obstacles and perspectives for future research and clinical translation of these contrast agents are discussed. We hope this review provides insights for scientists and students with interest in this area. Graphical abstract
first_indexed 2024-04-13T06:30:22Z
format Article
id doaj.art-cd0d965724024eaba568f3eae48e1006
institution Directory Open Access Journal
issn 1477-3155
language English
last_indexed 2024-04-13T06:30:22Z
publishDate 2022-06-01
publisher BMC
record_format Article
series Journal of Nanobiotechnology
spelling doaj.art-cd0d965724024eaba568f3eae48e10062022-12-22T02:58:10ZengBMCJournal of Nanobiotechnology1477-31552022-06-0120112110.1186/s12951-022-01479-6Recent development of contrast agents for magnetic resonance and multimodal imaging of glioblastomaDanping Zhuang0Huifen Zhang1Genwen Hu2Bing Guo3The Second Clinical Medical College, Jinan UniversityDepartment of Radiology, Shenzhen People’s Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology)Department of Radiology, Shenzhen People’s Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology)School of Science and Shenzhen Key Laboratory of Flexible Printed Electronics Technology, Harbin Institute of TechnologyAbstract Glioblastoma (GBM) as the most common primary malignant brain tumor exhibits a high incidence and degree of malignancy as well as poor prognosis. Due to the existence of formidable blood–brain barrier (BBB) and the aggressive growth and infiltrating nature of GBM, timely diagnosis and treatment of GBM is still very challenging. Among different imaging modalities, magnetic resonance imaging (MRI) with merits including high soft tissue resolution, non-invasiveness and non-limited penetration depth has become the preferred tool for GBM diagnosis. Furthermore, multimodal imaging with combination of MRI and other imaging modalities would not only synergistically integrate the pros, but also overcome the certain limitation in each imaging modality, offering more accurate morphological and pathophysiological information of brain tumors. Since contrast agents contribute to amplify imaging signal output for unambiguous pin-pointing of tumors, tremendous efforts have been devoted to advances of contrast agents for MRI and multimodal imaging. Herein, we put special focus on summary of the most recent advances of not only MRI contrast agents including iron oxide-, manganese (Mn)-, gadolinium (Gd)-, 19F- and copper (Cu)-incorporated nanoplatforms for GBM imaging, but also dual-modal or triple-modal nanoprobes. Furthermore, potential obstacles and perspectives for future research and clinical translation of these contrast agents are discussed. We hope this review provides insights for scientists and students with interest in this area. Graphical abstracthttps://doi.org/10.1186/s12951-022-01479-6GlioblastomaMRIblood–brain barrierContrast agents
spellingShingle Danping Zhuang
Huifen Zhang
Genwen Hu
Bing Guo
Recent development of contrast agents for magnetic resonance and multimodal imaging of glioblastoma
Journal of Nanobiotechnology
Glioblastoma
MRI
blood–brain barrier
Contrast agents
title Recent development of contrast agents for magnetic resonance and multimodal imaging of glioblastoma
title_full Recent development of contrast agents for magnetic resonance and multimodal imaging of glioblastoma
title_fullStr Recent development of contrast agents for magnetic resonance and multimodal imaging of glioblastoma
title_full_unstemmed Recent development of contrast agents for magnetic resonance and multimodal imaging of glioblastoma
title_short Recent development of contrast agents for magnetic resonance and multimodal imaging of glioblastoma
title_sort recent development of contrast agents for magnetic resonance and multimodal imaging of glioblastoma
topic Glioblastoma
MRI
blood–brain barrier
Contrast agents
url https://doi.org/10.1186/s12951-022-01479-6
work_keys_str_mv AT danpingzhuang recentdevelopmentofcontrastagentsformagneticresonanceandmultimodalimagingofglioblastoma
AT huifenzhang recentdevelopmentofcontrastagentsformagneticresonanceandmultimodalimagingofglioblastoma
AT genwenhu recentdevelopmentofcontrastagentsformagneticresonanceandmultimodalimagingofglioblastoma
AT bingguo recentdevelopmentofcontrastagentsformagneticresonanceandmultimodalimagingofglioblastoma